How Two Plants Become One Establishment Number

"If a supplier tells you a plant cannot be expanded, what has it just told you about your next three years?"

We covered half of this on Aug 9, off Note 18 of a 10-Q, and said the filing named no capacity figure, no North Carolina site and no closure date.

True of the filing. Not true of the day.

STERIS published the site, the money and the reason the same afternoon, in three documents that never touch EDGAR. The reason is the part that belongs in your file.

Here is Dan Carestio, on the Aug 6 call, describing the two US plants that make the company's formulated chemistries:

"The problem is that neither are really expandable, and both are going to be bumping up against the upper limits of capacity in the future."

That is a producer telling the market its own supply is running out of headroom. Everything after it is the price and the calendar of getting that headroom back.

Two Acquisitions That Never Merged

St. Louis and Plymouth did not grow up together. They arrived twenty-five years apart, attached to deals.

St. Louis came in with Calgon Vestal Laboratories in 1996, the same year STERIS bought AMSCO. The address, 7501 Page Ave., still prints on the company's EPA labels three decades later.

Plymouth, Minnesota came in with Cantel Medical in 2021, along with the endoscope reprocessing chemistries and high-level disinfectants that Cantel's Medivators business sold.

So the consolidation is the integration nobody did in 2021, finally being done in concrete. Carestio put the businesses served at more than $700m of annual revenue, which is a number the segment tables do not carry: these chemistries sit inside Healthcare consumables ($391.9m in the June quarter) and Life Sciences consumables ($81.5m, up from $75.3m a year earlier) rather than in a line of their own.